BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27790753)

  • 1. Renal dysfunction in patients taking fumaric acid esters - a retrospective cross-sectional study.
    Menzies S; Ismail N; Abdalla A; Collins P; Kirby B; Holian J; Lally A
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):686-691. PubMed ID: 27790753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteinuria with fumaric acid ester treatment for psoriasis.
    Ogilvie S; Lewis Jones S; Dawe R; Foerster J
    Clin Exp Dermatol; 2011 Aug; 36(6):632-4. PubMed ID: 21771009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
    Balasubramaniam P; Stevenson O; Berth-Jones J
    Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatment with fumaric acid esters in six paediatric patients with psoriasis in a psoriasis centre.
    Steinz K; Gerdes S; Domm S; Mrowietz U
    Dermatology; 2014; 229(3):199-204. PubMed ID: 25247273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis.
    Hoefnagel JJ; Thio HB; Willemze R; Bouwes Bavinck JN
    Br J Dermatol; 2003 Aug; 149(2):363-9. PubMed ID: 12932244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study.
    Mrowietz U; Christophers E; Altmeyer P
    Br J Dermatol; 1998 Mar; 138(3):456-60. PubMed ID: 9580799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longterm treatment of psoriasis using fumaric acid preparations can be associated with severe proximal tubular damage.
    Raschka C; Koch HJ
    Hum Exp Toxicol; 1999 Dec; 18(12):738-9. PubMed ID: 10627662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of fumaric acid esters in children with psoriasis: a retrospective analysis of 14 patients from The Netherlands.
    Balak DM; Oostveen AM; Bousema MT; Venema AW; Arnold WP; Seyger MM; Thio HB
    Br J Dermatol; 2013 Jun; 168(6):1343-7. PubMed ID: 23738641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.
    Dickel H; Bruckner T; Altmeyer P
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1710-1727. PubMed ID: 29705996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care.
    Mrowietz U; Sorbe C; Reich K; Von Kiedrowski R; Weckbecker J; Radtke MA; Rustenbach SJ; Augustin M
    Eur J Dermatol; 2020 Feb; 30(1):41-48. PubMed ID: 32250255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study).
    Reich K; Hartl C; Gambichler T; Zschocke I
    J Dtsch Dermatol Ges; 2016 Jan; 14(1):50-8. PubMed ID: 26713639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study.
    Wain EM; Darling MI; Pleass RD; Barker JN; Smith CH
    Br J Dermatol; 2010 Feb; 162(2):427-34. PubMed ID: 19519838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fumaric acid ester-induced T-cell lymphopenia in the real-life treatment of psoriasis.
    Dickel H; Bruckner T; Höxtermann S; Dickel B; Trinder E; Altmeyer P
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):893-905. PubMed ID: 30680823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulated genes in psoriatic skin during treatment with fumaric acid esters.
    Onderdijk AJ; Balak DM; Baerveldt EM; Florencia EF; Kant M; Laman JD; van IJcken WF; Racz E; de Ridder D; Thio HB; Prens EP
    Br J Dermatol; 2014 Oct; 171(4):732-41. PubMed ID: 24852654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases.
    Harries MJ; Chalmers RJ; Griffiths CE
    Br J Dermatol; 2005 Sep; 153(3):549-51. PubMed ID: 16120141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE).
    Reich K; Thaci D; Mrowietz U; Kamps A; Neureither M; Luger T
    J Dtsch Dermatol Ges; 2009 Jul; 7(7):603-11. PubMed ID: 19459898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug survival of fumaric acid esters for psoriasis: a retrospective study.
    Ismail N; Collins P; Rogers S; Kirby B; Lally A
    Br J Dermatol; 2014 Aug; 171(2):397-402. PubMed ID: 24471408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of an oral histamine antagonist to reduce adverse events associated with fumaric acid esters in the treatment of psoriasis: a randomized double-blind placebo-controlled trial.
    Balak DM; Fallah-Arani S; Venema CM; Neumann HA; Thio HB
    Br J Dermatol; 2015 Mar; 172(3):754-9. PubMed ID: 25041291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fumaric acid esters for psoriasis: a systematic review.
    Smith D
    Ir J Med Sci; 2017 Feb; 186(1):161-177. PubMed ID: 27271164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis.
    Höxtermann S; Nüchel C; Altmeyer P
    Dermatology; 1998; 196(2):223-30. PubMed ID: 9568412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.